Background. Specific blockade of T cell costimulation pathway is a promising immunomodulatory approach being developed to replace our current clinical immunosuppression therapies. The goal of this study is to compare results associated with 3 monoclonal antibodies directed against the CD40/CD154 T cell costimulation pathway. Methods. Cynomolgus monkey heterotopic cardiac allograft recipients were treated with either IDEC-131 (humanized αCD154, n = 9), 5C8H1 (mouse-human chimeric αCD154, n = 5), or 2C10R4 (mouse-rhesus chimeric αCD40, n = 6) monotherapy using a consistent, comparable dosing regimen for 3 months after transplant. Results. Relative to the previously reported IDEC-131-treated allografts, median survival time (35 ± 31 days) was significantly prolonged in both 5C8H1-treated (142 ± 26, P < 0.002) and 2C10R4-treated (124 ± 37, P < 0.020) allografts. IDEC-131-treated grafts had higher cardiac allograft vasculopathy severity scores during treatment relative to either 5C8H1 (P = 0.008) or 2C10R4 (P = 0.0002). Both 5C8H1 (5 of 5 animals, P = 0.02) and 2C10R4 (6/6, P = 0.007), but not IDEC-131 (2/9), completely attenuated IgM antidonor alloantibody (alloAb) production during treatment; 5C8H1 (5/5) more consistently attenuated IgG alloAb production compared to 2C10R4 (4/6) and IDEC-131 (0/9). All evaluable explanted grafts experienced antibody-mediated rejection. Only 2C10R4-treated animals exhibited a modest, transient drop in CD20 + lymphocytes from baseline at day 14 after transplant (−457 ± 152 cells/μL) compared with 5C8H1-treated animals (16 ± 25, P = 0.037), and the resurgent B cells were primarily of a naive phenotype. Conclusions. In this model, CD154/CD40 axis blockade using IDEC-131 is an inferior immunomodulatory treatment than 5C8H1 or 2C10R4, which have similar efficacy to prolong graft survival and to delay cardiac allograft vasculopathy development and antidonor alloAb production during treatment.
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Background. Specific blockade of T cell costimulation pathway is a promising immunomodulatory approach being developed to replace our current clinical immunosuppression therapies. The goal of this study is to compare results associated with 3 monoclonal antibodies directed against the CD40/CD154 T cell costimulation pathway. Methods. Cynomolgus monkey heterotopic cardiac allograft recipients were treated with either IDEC-131 (humanized αCD154, n = 9), 5C8H1 (mouse-human chimeric αCD154, n = 5), or 2C10R4 (mouse-rhesus chimeric αCD40, n = 6) monotherapy using a consistent, comparable dosing regimen for 3 months after transplant. Results. Relative to the previously reported IDEC-131-treated allografts, median survival time (35 ± 31 days) was significantly prolonged in both 5C8H1-treated (142 ± 26, P < 0.002) and 2C10R4-treated (124 ± 37, P < 0.020) allografts. IDEC-131-treated grafts had higher cardiac allograft vasculopathy severity scores during treatment relative to either 5C8H1 (P = 0.008) or 2C10R4 (P = 0.0002). Both 5C8H1 (5 of 5 animals, P = 0.02) and 2C10R4 (6/6, P = 0.007), but not IDEC-131 (2/9), completely attenuated IgM antidonor alloantibody (alloAb) production during treatment; 5C8H1 (5/5) more consistently attenuated IgG alloAb production compared to 2C10R4 (4/6) and IDEC-131 (0/9). All evaluable explanted grafts experienced antibody-mediated rejection. Only 2C10R4-treated animals exhibited a modest, transient drop in CD20 + lymphocytes from baseline at day 14 after transplant (−457 ± 152 cells/μL) compared with 5C8H1-treated animals (16 ± 25, P = 0.037), and the resurgent B cells were primarily of a naive phenotype. Conclusions. In this model, CD154/CD40 axis blockade using IDEC-131 is an inferior immunomodulatory treatment than 5C8H1 or 2C10R4, which have similar efficacy to prolong graft survival and to delay cardiac allograft vasculopathy development and antidonor alloAb production during treatment. C urrent clinical immunosuppressive regimens are incompletely effective at preventing chronic rejection and are associated with a myriad of adverse effects. Considerable attention has thus been given to exploring alternative immunomodulatory approaches. The 2 major T cell costimulation pathways that provide second signals required for T cell activation, CD28/B7 (CD80/CD86) and CD40/CD154 (CD40L), have been identified as logical targets to improve clinical transplant outcomes. The CD40/CD154 pathway plays a pivotal role in T cell-mediated dendritic cells (DC) and macrophage activation, development of Th1-type immune responses, and cytotoxic T cell priming. 1 As such, considerable effort has been directed toward the development of clinically useful antibodies to both CD40 and CD154 for the protection of graft rejection in transplantation and for the treatment of autoimmune disease.
CD154 is a member of the TNF family and is rapidly induced on T cells after T cell receptor activation. By targeting activated T cells, αCD154 demonstrated prolonged acute rejection-free periods after allotransplantation in nonhuman primate (NHP) renal, 2-5 skin, 6 heart, 7 and islet cells allografts. 8 However, preclinical and human clinical trials of αCD154 were thwarted by thromboembolic (TE) complications, [9] [10] [11] which is likely due to expression of CD154 on activated platelets that stabilizes arterial thrombi in a CD40-independent manner. 12, 13 Hence, αCD40 agents were developed in anticipation of an improved safety profile.
CD40 is a cell surface glycoprotein in the TNF receptor family that is widely expressed, both constitutively on antigen-presenting cells, including B cells, DCs, and macrophages, and induced after inflammatory stimulation on endothelial cells and fibroblasts. 1 Despite the ubiquitous nature of CD40, overt harmful downstream effects of CD40 blockade have not been demonstrated in other preclinical models, and clinical success has been demonstrated with several different αCD40 monoclonal antibody (mAb).
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Here we compare the efficacy of 3 contemporary mAbs that block the CD40/CD154 costimulation pathway, tested in a preclinical NHP model: IDEC-131 and 5C8H1, a mousehuman chimeric αCD154 mAbs, and 2C10R4, a mouserhesus chimeric αCD40 mAb.
MATERIALS AND METHODS

Animal Model
All protocols were approved by the Institutional Animal Care and Use Committee at the University of Maryland School of Medicine and were conducted in compliance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Captive-bred and wildcaught cynomolgus monkeys (Macaca fascicularis) of Chinese and Indonesian origin were used. Males and females weighing 2.9 to 9.7 kg were selected as organ recipients of ABO blood type-compatible donors. Major histocompatibility complex class II mismatch was ensured by maximizing mixed lymphocyte reaction response and achieving a stimulation index greater than 3 for each donor-recipient pair. The development of antidonor class I (T cell) alloantibody (alloAb) demonstrated class I mismatch. Animals that did not develop alloAb had genomic DNA Illumina sequencing spanning exon 2 for all class I loci (Madison, WI) to confirm a high degree of Mafa-A and Mafa-B class I mismatch.
Surgical Procedures
All recipients underwent heterotopic intra-abdominal cardiac transplantation, as described previously. 22 Open cardiac biopsies were performed by protocol on postoperative days (d) 14, 42, 90, and 150, if applicable. Biopsies were occasionally omitted or delayed due to anemia or weight loss. Core temperature and graft heart rate, systolic blood pressure, and diastolic blood pressure were assessed at least once daily using intra-abdominal telemetry (D70-PCTP or L11, Data Sciences International, St. Paul, MN) until time of graft explant.
Immunosuppression Treatment Groups and Dosing
5C8H1 is a mouse-human IgG1κ chimeric anti-CD154 antibody, and 2C10R4 is a mouse-rhesus IgG4κ anti-CD40 antibody. 21 Both were obtained from the NIH Nonhuman Primate Reagent Resource (Boston, MA). IDEC-131, a humanized IgG1 anti-CD154 mAb, was a gift from Biogen Idec Inc. (San Diego, CA). Three IDEC-131 recipients received IDEC-131 intravenously (IV) at 30 mg/kg on d0, d3, d7, and d14; 20 mg/kg on d28, d56, and d84 (total 180 mg/kg). This regimen was intensified, as described previously, 23 and subsequent recipients received either IDEC-131 (n = 6), 5C8H1 (n = 5), or 2C10R4 (n = 6) IV at 30 mg/kg on d0, d3, d7, and d14; 10 mg/kg on d21, d28, d35, and d42; 20 mg/kg on d56 and d84 (total 200 mg/kg).
In the IDEC-131 treatment group only, 3 monkeys with suspected or biopsy-confirmed rejection were treated with steroid boluses (Solu-Medrol, Pharmacia, Kalamazoo, MI; 10 mg/kg IV daily for 3 doses, n = 3), antithymocyte globulin (ATG; NR-ATG, DCI Inc., Nashville, TN or Thymoglobulin, Sangstadt, Menlo Park, CA; 10 mg/kg IV daily for 3 doses, n = 1), or with anti-CD20 rituximab (Rituxan, Genetech, South San Francisco, CA; 20 mg/kg IV once, n = 1; Table 1 ).
In the 2C10R4 treatment group, coagulated blood in ethylenediaminetetraacetic acid tubes on routine blood draws on d7-11 raised suspicion for hypercoagulability in 1 animal, and on d7 heparin (50 units/kg/hr IV for 2 days,15 units/kg per hour IV for the following 19 days) and aspirin (20 mg by mouth daily until day of rejection) were given (FB6E, Table 1 ). Routine monitoring for cytomegalovirus was not performed, and antiviral medications were not used.
Allograft Rejection and Failure Criteria
Primary graft survival was defined as time to first rejection episode or graft failure and served as the primary study endpoint for all survival analyses to minimize the bias of IDEC-131 receiving treatment for acute rejection episodes. Acute rejection episode criteria included 1 or more of the following: intra-abdominal body temperature greater than 38.5°C, decline in heart rate greater than 20% below baseline or less than 120 beats per minute, pulse pressure (systolicdiastolic in mm Hg) less than 30 mm Hg, or weak palpable graft contraction lasting longer than 12 hours. Graft failure was defined by 1 or more of the following criteria for 2 consecutive days: decline in heart rate greater than 20% below baseline or less than 120 beats per minute, pulse pressure less than 30 mmHg, or nonpalpable graft contraction.
Drug Trough Levels and Receptor Coverage
Serum trough αCD154 and αCD40 levels were checked retrospectively by enzyme-linked immunosorbent assay (Materials and Methods, SDC, http://links.lww.com/TP/B457). The peripheral blood CD40 receptor saturation was measured by flow cytometry before each 2C10R4 administration and biweekly after completion of the drug treatment. Peripheral blood was stained for CD20 (L27, BD Biosciences, San Jose, CA) and CD40 (5C8, Biolegend, San Diego, CA), and the CD40 saturation was calculated as the percentage of CD20 + CD40
+ among CD20 + cells subtracted from 100%. A tube with excess 2C10R4 served as positive control. The samples were processed on a Verse flow cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star, Ashland, OR).
Blood Collection and Lymphocyte Detection
Routine blood collection was performed, and lymphocytes were stained for flow cytometry and analyzed for CD20 + B memory cell phenotypes (Materials and Methods, SDC, http:// links.lww.com/TP/B457). 24, 25 Antidonor alloAb Detection Antidonor alloAb was measured retrospectively by flow cytometry using archived frozen donor splenocytes and recipient sera, as described previously. 26, 27 Antidonor alloAb elaboration was defined as consistently detected IgM-positive or IgG-positive donor CD3 + CD20
− T cells greater than 10% relative to donor serum before transplant. 28 
Histology and Cardiac Allograft Vasculopathy Grading
Biopsy and explant cardiac tissue specimens were fixed with 10% formalin, processed for paraffin embedding, and stained with hematoxylin and eosin. Cellular myocardial infiltrates were classified by the 2005 International Society for Heart and Lung Transplantation (ISHLT) revised criteria for cardiac allograft rejection. 29 Cardiac allograft vasculopathy (CAV) severity with hematoxylin and eosin staining was scored on an average of 3 ± 0.3 and 28 ± 2.5 vessels in each biopsy and explanted graft specimen, respectively, by 3 independent evaluators (N.A.O. or L.B., T.Z., and R.N.P.), who were blinded with respect to treatment group. 26 Biopsies with poor tissue preservation or absence of identifiable myocardial tissue were classified as nondiagnostic. Pericardial granulation tissue was excluded from rejection and CAV assessments.
Immunofluorescence Staining and Antibody-Mediated Rejection Score
Evaluable cardiac tissue specimens were stained for CD68 + and C4d and scored using the 2013 ISHLT guidelines for antibody-mediated rejection (AMR) scoring (Materials and Methods, SDC, http://links.lww.com/TP/B457). 30 Cellular infiltration of explanted allografts by CD3 + and CD20 + lymphocytes was evaluated in a similar manner. Each explant had 8 to 9 representative images per staining and was independently scored by 3 blinded evaluators (N.A. O., T.Z., and C.T.L.). The mean score of the representative images per graft was reported (Table S1 , SDC, http://links. lww.com/TP/B457).
Statistical Analysis
Survival analysis was examined by the Kaplan-Meier method and compared by log-rank test. Continuous variables were expressed as the mean ± SEM or median and interquartile ranges (IQR), and these were compared using either the 2-tailed unpaired t test to compare 2 groups or as analysis of variance to compare 3 or more groups. Nominal variables were compared using a contingency table and the Fisher exact test. P values less than 0.05 were considered statistically significant. All statistical analyses were performed on a personal computer with GraphPad InStat (version 3.01; GraphPad Software, San Diego, CA).
RESULTS
Pharmacokinetics
IDEC-131, 5C8H1, and 2C10R4 serum trough levels were generally greater than 300 μg/mL for the first month and greater than 100 μg/mL for the 90 days after transplantation ( Figure 1A ). Trough levels during the 90-day treatment for 2C10R4-treated allografts (mean ± SEM; 376 ± 22 μg/mL) were significantly higher than IDEC-131-treated allografts (289 ± 20; P = 0.005) but not different than the 5C8H1 group. CD40 receptor coverage was nearly 100% in 2C10R4-treated animals through d118 ( Figure 1B) . 
Allograft Survival
The median survival time of 5C8H1 (142, range 90-173 days, n = 5, P < 0.001) or 2C10R4 (124; range, 25-178, n = 6, P = 0.002) was significantly longer than IDEC-131-treated allograft recipients (35; range, 9-112, n = 9, Figure 2) . One of the 6 2C10R4-treated animals (FC9J, 89 days, serum trough level 239 μg/mL, 88% receptor coverage) experienced rejection within the 90-day treatment period, and another animal (FA53, 2C10R4, d117) experienced graft rejection and subsequent failure with 100% receptor coverage and low (41 μg/mL) serum trough levels. Two animals in the 2C10R4 treatment group (FB9N and DV36) and 1 animal (MDL5X) in the 5C8H1 group had functional, beating allografts removed per protocol or for health reasons (Table 1 ). All allografts in the IDEC-131 treatment group were explanted due to graft failure from rejection.
Three IDEC-131-treated allografts that demonstrated evidence of clinically overt acute rejection (M51, M327, and M348) received steroids (Table 1) . Although 1 animal additionally received ATG (M51) and recovered graft function from this early acute rejection episode, both M327 and M348 failed to recover function and were explanted shortly thereafter.
Acute Cellular Infiltration Histology
Acute cellular rejection, as graded by ISHLT score, increased significantly within each treatment group as time after transplantation increased (IDEC-131 P = 0.01; 5C8H1 P = 0.02; 2C10R4 P = 0.02; Figure 3 , Figure S1 , SDC, http://links.lww.com/TP/B457), but there was no significant difference between treatment groups and median ISHLT scores graded on biopsies or explanted grafts at less than 30, 30 to 89, 90 to 119, or 120 days or longer.
Myocardial cellular infiltration of rejected explants in each treatment group was predominately CD68 + macrophages and CD3 + T cells with scattered foci of CD20 + B cells (Figure 4 ). Although the CD3 + infiltration scores were similar across the 3 treatment groups, 5C8H1-treated grafts had significantly more CD20 + cells (mean score 0.3 ± 0.2) than IDEC-131-treated grafts (0.1 ± 0.0; P = 0.04, Figure 4C ).
CAV Histology
CAV severity scores increased significantly from time of transplant to explant in both the IDEC-131 (P < 0.0001) FIGURE 1. A, Mean serum trough levels measured by ELISA for IDEC-131 (green), 5C8H1 (blue), and 2C10R4 (red) with SEM in negative error bars. Open circles represent drug dosing: 30 mg/kg on d0, d3, d7, d14; 10 mg/kg on d21, d28, d35, d42; 20 mg/kg on d56 and d84. B, Mean peripheral blood CD40 receptor coverage (%) measured by flow cytometry for 2C10R4 (red) with SEM demonstrated in error bars. Open circles represent drug dosing, as above. Receptor coverage was nearly 100% through d118, which coincided with 2C10R4 trough levels falling below 100 μg/mL. ELISA, enzyme-linked immunosorbent assay. FIGURE 2. Allograft survival. Primary graft survival was defined as the time to first rejection episode or graft failure and served as the primary study endpoint for all survival. Graft failure was defined by 1 or more of the following criteria for 2 consecutive days: decline in heart rate greater than 20% below baseline or less than 120 beats per minute, pulse pressure less than 30 mmHg, or nonpalpable graft contraction. Allograft MST is significantly longer in the 5C8H1 (142 ± 26 days, p < 0.001) and 2C10R4 (124 ± 37, p = 0.002) treatment groups than IDEC-131 (35 ± 31). (+) represent allografts removed without evidence of rejection, and are censored from survival analyses. MST, median survival time.
FIGURE 3. Median ISHLT scores represented in box and whisker plot from all protocol biopsies and explanted allografts. Median ISHLT scores within each treatment group increased as time after transplantation increased. There was not a significant difference between treatment groups and median ISHLT scores at any time after transplantation. and 2C10R4 treatment groups (P = 0.01; Figure 5 , Figure S2 , SDC, http://links.lww.com/TP/B457). In 5C8H1-treated allografts, CAV biopsy scores were heterogeneous after transplantation. Biopsies and explanted grafts from 30 to 89 days, which are under treatment, had significantly higher CAV scores in the IDEC-131-treated grafts (median, 2.0; IQR, 1.8-2.4) compared to either 5C8H1-treated (median, 0.8; IQR, 0.4-0.8; P = 0.008) or 2C10R4-treated grafts (median, 0.4; IQR, 0.3-1.1; P = 0.0002), which is consistent with the earlier graft failure in the IDEC-131 group. A representative myocardial vessel with severe CAV is shown in Figure S3 , SDC, http://links.lww.com/TP/B457.
Antidonor alloAb Production
Overall, incidence of antidonor alloAb production during treatment was less with 5C8H1 (IgM: 0/5 animals, P = 0.02; IgG: 0/5, P = 0.0005, Figure 6 , middle panel) and 2C10R4 (IgM: 0/6, P = 0.007; IgG: 2/6, P = 0.01, Figure 6 , bottom panel) than IDEC-131-treated allografts (IgM: 7/9; IgG: 9/9, Figure 6 , top panel). In the IDEC-131 group, IgM alloAb elaboration preceded the explant of 7 allografts by 26 ± 13 days ( Figure 6 , left top panel), and IgG alloAb elaboration preceded all allograft explants by 27 ± 12 days ( Figure 6 , right top panel).
In 5C8H1-treated allografts, IgM and IgG alloAb were detected before rejection in only 1 animal (MFA6L) 149 days after transplant, which was 65 and 24 days, respectively, after treatment cessation at 84 days and before rejection and explant of the allograft at 173 days. At the time of explant, IgM alloAb was detected in 3 of 4 5C8H1-treated recipients ( Figure 6 , left middle panel), and IgG alloAb was detected in 2 of 4 recipients ( Figure 6 , right middle panel).
In the 2C10R4-treated allografts, IgM alloAb elaboration was detected in 1 animal (FB6E) 154 days after transplant, which was 24 days before rejection and explant ( Figure 6 , left bottom panel), and coincided with explant in a second animal (DV2R). IgG alloAb elaboration preceded explant in 3 animals by 19 ± 5 days and coincided with explant in the fourth animal (DV2R). No statistically significant difference in alloAb elaboration was detected at 90 days or graft failure between the 5C8H1-and 2C10R4-treated allograft recipients.
AMR Score
Given this striking pattern of alloAb development, AMR was scored on rejected explanted allografts. All evaluable explants demonstrated evidence of AMR, and cumulative pathologic AMR scores were similar between the 3 groups (Table S1, SDC, http://links.lww.com/TP/B457). The C4d capillary distribution scores were significantly higher in the 5C8H1-treated (1.5 ± 0.2; P = 0.03) and 2C10R4-treated (1.6 ± 0.2; P = 0.01) than IDEC-131-treated allografts (0.5 ± 0.2; Figures 7A-B) . Distribution of intravascular CD68 + macrophages was similar across treatment groups (Figures 7C-D) . + T cell cellular infiltration score in rejected explanted allografts (0, <10%; 1, 10% to 50%; 2, > 50% infiltration) was similar in each treatment group. C, Mean CD20 + Tcell cellular infiltration score in rejected explanted allografts using the same scoring system above. 5C8H1-treated animals had significantly higher CD20 + T cell infiltration than IDEC-131-treated animals. *P = 0.04.
FIGURE 5.
Median CAV scores from all protocol biopsies and explanted allografts represented in box and whisker plot. CAV scoring system is as follows: 0, 0% intimal hyperplasia; 1, less than 10%; 2, 10-50%, 3, greater than 50%. Biopsies and explanted grafts from 30 to 89 days after transplantation in the IDEC-131-treated allografts had significantly higher CAV than the 5C8H1-and 2C10R4-treated allografts. *P = 0.0005.
Blood Lymphocytes
Peripheral blood CD20 + lymphocytes in 5C8H1-treated animals increased significantly from d0 (568 ± 69 cells/μL) to d90 (934 ± 101, P = 0.024), whereas the number of CD20 + cells remained similar from d0 (913 ± 220 cells/μL) to d90 (1477 ± 370) in 2C10R4-treated animals. On d14 after transplant, there was a modest, though significant, drop in CD20 + lymphocytes from baseline in the 2C10R4-treated animals (−457 ± 152 cells/μL) compared to 5C8H1-treated animals (16 ± 25, P = 0.037; Figure 8A , Figure S4 , SDC, http://links.lww.com/TP/B457). After recovery of this B cell reduction in 2C10R4-treated animals, a naive B cell phenotype predominated (Figures 8D and F) . Memory B cell phenotype in the 1 evaluable 5C8H1-treated animal (MFA6L) remained generally stable after transplantation ( Figures 8C and E) .
Peripheral blood CD3 + lymphocytes after transplantation did not differ significantly from d0 in either the 5C8H1-or 2C10R4-treated animals or between treatment groups at any point ( Figure 8B) .
Anecdotally, 1 animal (FB6E) was noted to have coagulated blood in ethylenediaminetetraacetic acid tubes on 2 routine blood draws on d7-11. This observation led to a clinical decision to deploy a 3-week heparin drip and oral aspirin. No clinically significant TE event was noted in any animal in this treatment group, and hypercoagulability was not observed in association with either of the 2 unexpected, unexplained deaths that occurred in the group treated with 2C10R4.
DISCUSSION
Selective inhibition of one or more of the T cell costimulation pathways has been shown to increase allograft survival, delay or prevent elaboration of antidonor alloAb, and attenuate chronic rejection. 23, 31, 32 As predicted by extensive work in murine models, our prior work in NHP has shown that CD40/CD154 blockade is tolerogenic to influenza vaccination, 33 which prompted our initial evaluation of this treatment in a cardiac transplant model. As a predicate for exploring the combination of novel immunomodulatory strategies 32 with optimized blockade of the CD40/CD154 axis to promote peripheral regulatory tolerance, here we report a preclinical comparison of 3 mAb drug candidates that block CD40 (2C10R4) or CD154 (IDEC-131, 5C8H1).
As previously reported, blockade of αCD154 by IDEC-131 significantly, albeit modestly, increased median allograft survival from 6 to 39 days. 7, 23, 34 By using a directly comparable treatment regimen, here we show that both 5C8H1 and 2C10R4 significantly prolong cardiac allograft survival compared with historical IDEC-131-treated allografts. Additionally, 5C8H1 and 2C10R4 are each associated with improved control of pathogenic immunity, as demonstrated by reduced CAV severity scores during the second and third months of treatment and attenuation of alloAb development during treatment relative to IDEC-131, which is concordant with findings in several different NHP models using 5C8H1 or 2C10R4. [2] [3] [4] [5] [6] [7] [8] 20, 35 Although the trend toward lower concentrations of IDEC-131 may also have played a role, the stark increase in allograft survival with 5C8H1 compared with IDEC-131 is likely attributable to the differences in recognized CD154 epitopes, reduced binding affinity of IDEC-131 to CD154, Fc-related functionality, or some combination of these factors.
Neither transient CD40 nor CD154 blockade alone could induce a state of tolerance. As trough levels, and receptor coverage in the 2C10R4 group, declined after cessation of treatment, allografts were invariably rejected. The single 2C10R4-treated animal with 100% receptor coverage at the time of rejection (d117) and the animal with rejection within the 90-day treatment period (FC9J; d89, serum trough level 239 μg/mL, 88% receptor coverage on date of explant) suggest a pathway for αCD40-independent rejection. Several plausible mechanisms may explain this finding. We hypothesize that the broad distribution and constitutive expression of CD40 on cells of hematopoietic origin may decrease the effective concentration of 2C10R4 in the secondary lymphoid organs and in the graft where "professional" antigen presentation occurs. In addition, binding of 2C10R4 to soluble CD40 in plasma may artificially increase reported plasma levels of 2C10R4 to the extent that 2C10R4-CD40 complexes are detected in our assay. In contrast, CD154 is conditionally expressed after signal 1-mediated T cell activation. In the absence of a reservoir of antigen in plasma, effective concentrations of free 5C8H1 may be higher and, thus, available to more efficiently inhibit T cell-DC and T cell-B cell interactions. Unfortunately, due to this induced expression of CD154, we do not have an assay developed to reliably measure receptor coverage in these animals. Alternatively, T cells may receive a costimulation signal via another pathway, such as CD28/B7 or another costimulatory pathway. We are currently evaluating the combination of different agents that block the CD40/CD154 and B7/CD28 T cell costimulation pathways 36 to determine if these agents provide any synergy. Treatment with αCD40 and αCD154 is thought to inhibit B cell sensitization or maturation, 1, 20 and the consequential inhibition of, or delay in, production of antidonor alloAb is thought to be an important mechanism by which these treatments inhibit or delay acute and chronic rejection. Here we show delayed elaboration of both IgM and IgG antidonor alloAb during ongoing treatment and for variable intervals after the 90-day treatment in all evaluable 5C8H1-treated animals and 2 of the 4 evaluable 2C10R4-treated animals. In the 2 2C10R4 animals with potential αCD40-independent rejection, alloAb was detected before clinical evidence of rejection The blue (DAPI) illustrates staining of cell nuclei. Original magnification, Â200. C, Mean C4d capillary distribution score per ISHLT guidelines: 0, less than 10%; 1, 10% to 50%/focal staining; 2, greater than 50%/multifocal or diffuse staining. Capillary C4d staining was significantly lower in IDEC-131-treated allografts compared to either 5C8H1-or 2C10R4-treated. *P = 0.01. D, Mean intravascular CD68 + cell distribution score (0, <10%; 1, 10% to 50%/focal; 2, greater than 50%/multifocal or diffuse intravascular macrophages) was similar in each treatment group. and graft failure. When evaluating explant AMR scores, 5C8H1 and 2C10R4 groups had similar capillary C4d and intravascular CD68 + macrophages distribution patterns, which were both higher than IDEC-131-treated animals likely because of prolonged graft survival and exposures to subclinical episodes of rejection. Overall, αCD40/CD154 could delay, though not completely prevent, development of AMR.
Although preclinical and clinical trials using αCD154 were complicated by TE complications, 9-11 likely due to CD154 expression on activated platelets, subsequent studies found reduced TE rates with perioperative heparin or ketorolac administration. 37 Although our study was not designed to evaluate the frequency of subclinical thromboembolic events, we did not observe any clinical events associated with 5C8H1 (or the other agents used here), even without routine heparin or nonsteroidal anti-inflammatory drug use. Because CD154 can also circulate in a soluble form, sCD154 could potentially complex with αCD154 antibodies in the circulation, and such immune complexes were shown to potently activate platelets and cause thrombosis via the FcγRIIA IgG receptor. 38 A novel αCD154 blocking reagent that lacks the Fc domain, CDP7657, reportedly does not induce TE events in NHP 39 and is currently under evaluation for safety in patients with systemic lupus erythematosus (Clinicaltrials.gov Identifier NCT01764594). In our estimation, this promising development coupled with our current observations justify future studies to reevaluate αCD154 treatment in preclinical transplantation models, and in the clinic, based on the favorable immunomodulatory effects shown in this and other studies.
Nevertheless, the TE complications in 5C8H1 clinical trials motivated us, and others, to evaluate CD40 blockade as an alternative. Initially, a chimeric mouse antihuman CD40 with human IgG1 mAb, Chi220, was developed and studied in NHP renal 40 and islet models 36 ; however, this treatment FIGURE 8. Peripheral blood CD20 + (A) and CD3 + (B) lymphocytes were measured using flow cytometry for 5C8H1-treated (blue) and 2C10R4-treated (red) cardiac allograft recipients. Absolute cell numbers were calculated using complete blood count (CBC) data, and data are shown here as a change in absolute cell number from baseline (group mean ± SEM). Proportion of memory B cell phenotype amongst CD20 + B cells using flow cytometry in 5C8H1 (n = 1, C) and 2C10R4 (n = 6, D). Absolute cell number of memory B cell calculated from CBC data is shown in 5C8H1 (n = 1, E) and 2C10R4 (n = 6, F). After the reduction of circulating peripheral blood B cells in 2C10R4, a naive B cell phenotype (CD27 was found to profoundly deplete and activate B cells, was highly immunogenic due to the chimeric nature of the mAb, and was associated with multiple morbidities attributable to over-immunosuppression. 36, 40, 41 In part, this may be due to IgG1 engineered heavy chain epitopes that can bind Fcreceptors and activate complement. 16, 21, 36, 40 Importantly, the Fc region of the 2C10R4 antibody we used in this study is of the IgG4 subclass to reduce complement and Fcγ receptor binding. 42 Whether the antibody could initiate activation of CD40 expressing cells including endothelial cells has not been formally verified, but it is unlikely based on the absence of in vitro B cell activation by 2C10R4. 21 Although 2C10R4 is a nondepleting IgG4 isotype, in our study CD20 + B cells mildly, but consistently, dropped by about 500 cells/μL in 2C10R4-treated allograft recipients 2 weeks after transplantation, similar to previous studies. 20, 21 The relative decrease in B cells was self-limiting, with B cells generally returning to baseline by d35, and was unlike the large degree of depletion seen with previously developed IgG1 isotype αCD40 mAb. 16, 21, 36, 39 Here we found a nonspecific decrease across all peripheral B cell phenotypes and a naive resurgent B cell phenotype. This transient reduction may be due to Fc-mediated homing out of the peripheral blood or sequestration events. Alternatively, B cell homeostasis may be impaired in absence of CD40 signals during intense and systemic CD40 blockade. 43 Severe weight loss (>25%) with 2C10R4 has been reported, 35 but we did not observe any clinically significant weight loss with our 2C10R4 monotherapy group (Table 1) .
Several other "nondepleting" αCD40 mAb have since been developed, including 4D11, 14, 15 3A8, 16 and ASKP1240, [17] [18] [19] in addition to 2C10R4. Overall, each of these reagents has demonstrated clinical success in NHP solid organ allotransplantation models. Based on this encouraging data, "nondepleting" αCD40 antibodies are moving forward in phase 2 clinical trials in kidney transplant recipients (Clinicaltrials. gov Identifier NCT01780844). In summary, our report is the first direct comparative evaluation of 3 monotherapy mAb that block the CD154/CD40 pathway of T cell activation in a stringent NHP cardiac allograft model. We report that CD154 blockade using IDEC-131 is inferior to 5C8H1 or CD40 blockade with 2C10R4 when administered according to a comparable dosing regimen. 5C8H1 and 2C10R4 have similar safety and efficacy profiles, and thus are both promising reagents for clinical translation and preclinical development of tolerance induction strategies.
